Biotech firm secures £4.5m funding to take ‘world-first’ implantable treatment for brain cancer to clinics

MedTech developing 'world-first' GBM treatment raises £4.5m

A Cheshire-based MedTech has secured £4.5 million of investment and grant funding to help transform treatment for glioblastoma (GBM) and potentially extend thousands of lives each year. QV Bioelectronics, based at Alderley Park, is said to have developed a world-first implantable device designed to improve outcomes for patients with hard-to-treat GBM.  Cancer Research UK says glioblastoma accounted for around 32% of all brain tumours diagnosed i…

Biotech firm secures £4.5m funding to take ‘world-first’ implantable treatment for brain cancer to clinics

Investment led by GMC Life Sciences Fund by PXN Ventures and NPIF II – PXN Equity Finance

Brain Cancer Device Raises £4.5m To Transform Treatment For Aggressive Tumours

A Cheshire medical technology company has secured £4.5 million in investment to develop a groundbreaking implantable device that could significantly extend the lives of patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults.